Related Experiment Videos
Therapeutic alternatives in cutaneous T-cell lymphoma
K B Holloway1, F P Flowers, F A Ramos-Caro
1Department of Medicine, University of Florida College of Medicine, Gainesville.
Journal of the American Academy of Dermatology
|September 1, 1992
Summary
Cutaneous T-cell lymphoma (CTCL) includes mycosis fungoides and Sézary syndrome. Early-stage CTCL is treated with topical therapies, while advanced stages may require systemic treatments.
Area of Science:
- Oncology
- Dermatology
- Hematology
Background:
- Mycosis fungoides and Sézary syndrome are types of cutaneous T-cell lymphoma (CTCL), a non-Hodgkin's lymphoma.
- CTCL primarily affects the skin, presenting as early-stage or advanced disease.
Purpose of the Study:
- To outline current treatment strategies for cutaneous T-cell lymphoma.
- To highlight the different therapeutic approaches based on disease stage and involvement.
Main Methods:
- Review of established treatment guidelines for CTCL.
- Categorization of therapies based on disease presentation (early-stage, erythroderma, extracutaneous involvement).
Main Results:
- Early-stage CTCL confined to the skin is managed with topical treatments like nitrogen mustard, psoralen phototherapy (PUVA), or total-skin electron beam therapy.
- Photopheresis is the primary treatment for erythroderma.
- Systemic therapy is reserved for refractory cases or those with initial extracutaneous disease.
Conclusions:
- Current treatment for CTCL involves a stepwise approach, starting with topical therapies for early disease.
- Advanced or refractory CTCL necessitates systemic treatments.
- There is a need for more randomized comparative trials to evaluate the efficacy of various CTCL treatment options.